Company Overview
| Stock Name | Luye Pharma |
|---|---|
| Stock Code | 02186 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們致力於在中國進行腫瘤科、心血管系統以及消化與代謝三個領域創新藥品的開發、生產、營銷及銷售。我們擁有29種產品,其中主要的產品有七種,專注於癌症、心血管疾病和糖尿病等高發疾病。 |
| Listing Date | 2014-07-09 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 山東煙台萊山區寶源路9號 |
| Business Address (Hong Kong) | 香港皇后大道中15號置地廣場告羅士打大廈8樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | luye.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 5.92 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2014-06-26 to 2014-07-02 |
| Global Offering Shares | 999,640,000 shares |
| HK Public Offer Shares (Initial) | 99,964,000 shares (10.0%) |
| Public Offer Lots (Initial) | 199,928lots (Pool A99,964lots,Pool B99,964lots) |
| International Placing Shares (Initial) | 899,676,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 3,321,073,843 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 11.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 5,917,868,800 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 8.55B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣327.9百萬元 |
| Period-End Cash Balance | 人民幣333.2百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2011 | 2012 | 2013 |
|---|---|---|---|
| Revenue | 1,774,390 | 2,135,943 | 2,515,111 |
| Cost of sales | -301,121 | -351,813 | -413,506 |
| Gross profit | 1,473,269 | 1,784,130 | 2,101,605 |
| Other income and gains, net | 25,934 | 12,717 | 35,902 |
| Selling and distribution expenses | -980,111 | -1,209,717 | -1,378,061 |
| Administrative expenses | -151,566 | -157,906 | -146,508 |
| Net finance costs | -19,636 | -29,145 | -24,091 |
| Share of associates and JVs | 545 | 894 | 990 |
| Profit before tax | 201,128 | 255,451 | 383,168 |
| Income tax expense | -34,902 | -79,862 | -55,224 |
| Profit for the year | 166,226 | 175,589 | 327,944 |
| Profit attributable to owners | 155,752 | 169,032 | 310,498 |
Balance Sheet
| Item | 2011 | 2012 | 2013 |
|---|---|---|---|
| Cash and cash equivalents | 251,501 | 364,031 | 333,150 |
| Trade and bills receivables | 455,326 | 514,258 | 535,562 |
| Inventories | 106,272 | 142,686 | 234,733 |
| Total current assets | 932,041 | 1,088,568 | 1,652,370 |
| Total current liabilities | 878,987 | 884,200 | 1,302,983 |
| Total equity | 1,404,387 | 1,583,807 | 1,897,695 |
| Equity attributable to owners | 1,287,557 | 1,460,420 | 1,769,042 |
| Interest-bearing borrowings | 455,815 | 470,787 | 745,308 |
Cash Flow Statement
| Item | 2011 | 2012 | 2013 |
|---|---|---|---|
| Net cash from operating activities | 313,420 | 152,902 | 439,626 |
| Net cash from investing activities | -608,112 | -135,130 | -554,376 |
| Net cash from financing activities | 144,963 | 91,517 | 87,320 |
| Net increase in cash | -149,729 | 109,289 | -27,430 |
| Depreciation of PP&E | 31,468 | 39,900 | 57,953 |
| Amortisation of intangible assets | 42,676 | 38,877 | 37,629 |
| Purchase of PP&E | -297,297 | -146,240 | -265,016 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 6.7 |
|---|---|
| First Day Open | HK$ 6.8 |
| First Day Change | 13.18% |
| First Day Volume | 258195000.0 |
| First Day Turnover | 1735020000.0 |
| Use of Proceeds | 1、所得款項凈額約20%或約718百萬港元用于通過引入授權及其他安排(包括選擇性獲取經批準藥品的生產權或銷售及市場推廣權),旨在補充我們的現有藥品組合;
2、所得款項凈額約20%或約718百萬港元用于研發(包括現有及未來中國及海外藥物開發項目)及涉及研發技術或進一步加強我們的研發能力及在研產品計劃的投資;
3、所得款項凈額約20%或約718百萬港元用于選擇性收購國內外醫藥公司;
4、所得款項凈額約20%或約718百萬港元用于撥充資本開支項目,通過構建新生產線以及升級及進一步推動現有生產設施自動化以增加我們的產能,以應對預期增加的我們目前產品及在研產品的需求;
5、所得款項凈額約5%或約180百萬港元用于通過雇傭額外的市場推廣及銷售人員(包括專注于中樞神經系統產品的專責銷售人員)擴展我們的銷售及市場推廣網絡,設立額外的地區辦事處以增強我們現有產品的市場滲透,實現我們成功開發的在研產品的商業化及提高市場推廣及促銷活動(包括我們通過內部銷售團隊進行的學術推廣)的水平;
6、所得款項凈額約5%或約180百萬港元將用于部份償還美元抵押貸款下的借款;
7、所得款項凈額約10%或約360百萬港元將用作營運資金及一般公司用途。
|
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Dragon Billion China Master Fund | 406,094,240 HKD | — | 2.06% | — | 6 months | 2015-01-09 |
| 2 | OrbiMed Funds | 406,094,240 HKD | — | 2.07% | — | 6 months | 2015-01-09 |
| 3 | TAL China Focus Master Fund | 243,658,320 HKD | — | 1.24% | — | 6 months | 2015-01-09 |
| 4 | 惠理基金管理香港有限公司 | 812,191,440 HKD | — | 4.13% | — | 6 months | 2015-01-09 |
| 5 | 麦格理基金管理(香港)有限公司 | 203,047,120 HKD | — | 1.03% | — | 6 months | 2015-01-09 |
| 6 | 五矿资本(香港)有限公司 | 203,047,120 HKD | — | 1.03% | — | 6 months | 2015-01-09 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 劉殿波 | — |
| Company Secretary | 黎少娟 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 綠葉投資持有45.4%(1,509,819,930股),劉殿波先生通過全權信託及受控制法團持有45.4%權益;CPE Greenery持有6.8%、CDH Flower持有6.4%、Beyond Border持有5.4%、Tropical Excellence持有5.9%。 |
|---|




